SEYED JALALI to Receptor, ErbB-2
This is a "connection" page, showing publications SEYED JALALI has written about Receptor, ErbB-2.
Connection Strength
1.024
-
Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model. Anticancer Agents Med Chem. 2017; 17(6):851-858.
Score: 0.402
-
Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS One. 2020; 15(12):e0243550.
Score: 0.132
-
P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artif Cells Nanomed Biotechnol. 2019 Dec; 47(1):665-673.
Score: 0.123
-
Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Curr Drug Deliv. 2017; 14(4):492-502.
Score: 0.100
-
Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol Lett. 2016 08; 176:57-64.
Score: 0.096
-
P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 2014 Dec 01; 355(1):54-60.
Score: 0.086
-
Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol Lett. 2014 Nov; 162(1 Pt A):87-93.
Score: 0.085